Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Vecuronium Stories

2012-06-28 14:21:27

BEDFORD, Ohio, June 28, 2012 /PRNewswire/ -- Bedford Laboratories((TM)) today announced a nationwide voluntary hospital/user-level recall for: Vecuronium Bromide for Injection, 20 mg vial - NDC #55390-039-10 Lot 2067134 - Exp. Date 5/31/2013First Shipment - 8/8/2011Last Shipment - 11/9/2011 Please note: This recall is for lot 2067134 only. No other lots of Vecuronium Bromide for injection Preservative Free are subject to this voluntary recall. (Logo:...

2012-01-10 14:41:00

BEDFORD, Ohio, Jan. 10, 2012 /PRNewswire/ -- Bedford Laboratories(TM) today issued updated guidance on the following nationwide voluntary product recalls originally issued on August 2, 2011: Polymyxin B for Injection USP, 500,000 Units per vial - NDC #55390-139-10Lot 1942980 - Exp. Date August 2013 and Lot 1895027 - Exp. Date June 2013 Vecuronium Bromide for Injection, 10 mg per vial - NDC #55390-037-10Lot 1865067 - Exp. Date May 2012 Vecuronium Bromide for Injection, 20...

2008-09-10 15:00:37

KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that the European launch of BRIDION(R) (sugammadex) injection has begun with its introduction this week in Sweden, and that the product is expected to be available soon in the United Kingdom and Germany, with several other European markets to follow by the end of the year and in early 2009. "The introduction of BRIDION in Europe represents an important advance for anesthesiologists and the...

2008-07-29 18:00:51

KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of anesthesia in two decades. BRIDION is indicated for routine reversal of the commonly used muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for...

2008-03-11 18:00:45

KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough today announced that the U.S. Food and Drug Administration (FDA) Advisory Committee on Anesthetics and Life Support has recommended sugammadex for approval. After reviewing data on the safety and efficacy of the medication, the committee unanimously recommended approval of the company's application for marketing. The FDA is not bound by the committee's recommendations; however, they usually are considered carefully...